These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3103269)

  • 1. A heat-treated factor VIII concentrate prepared by controlled-pore glass adsorption chromatography.
    Benny AG; Scott RH; Woodfield DG
    Transfusion; 1987; 27(2):174-7. PubMed ID: 3103269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled pore glass factor VIII concentrate: influence of heat treatment.
    Ockelford PA; Benny AG; Berry EW; Johns AS; Woodfield DG
    Pathology; 1987 Jan; 19(1):56-7. PubMed ID: 3108838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
    Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
    Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of stable intermediate-purity factor VIII concentrate with a note on high-purity factor VIII.
    Margolis J; Rhoades P
    Vox Sang; 1979; 36(6):369-74. PubMed ID: 494575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified glycine precipitation technique for the preparation of factor VIII concentrate of high purity and high stability.
    Brodniewicz-Proba T; Beauregard D
    Vox Sang; 1987; 52(1-2):10-4. PubMed ID: 3111087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
    Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
    Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of intermediate-purity factor VIII concentrate by direct gel filtration of cryoprecipitate.
    Teh LC
    Vox Sang; 1993; 65(4):251-7. PubMed ID: 8310677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A process for preparation of 'high-purity' factor VIII by controlled pore glass treatment.
    Margolis J; Gallovich CM; Rhoades P
    Vox Sang; 1984; 46(6):341-8. PubMed ID: 6431689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment.
    Smit Sibinga CT; Schulting PJ; Notebomer J; Das PC; Marrink J; vd Meer J
    Blut; 1988 Mar; 56(3):111-6. PubMed ID: 3128351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate.
    Hughes C; Thomas KB; Schiff P; Herrington RW; Polacsek EE; McGrath KM
    Transfusion; 1988; 28(6):566-70. PubMed ID: 3143170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severely heated therapeutic factor VIII concentrate of high specific activity.
    Winkelman L; Owen NE; Evans DR; Evans H; Haddon ME; Smith JK; Prince PJ; Williams JD; Lane RS
    Vox Sang; 1989; 57(2):97-103. PubMed ID: 2506696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of fibrinogen content in cryoprecipitate by temperature manipulation during plasma processing.
    Farrugia A; Grasso S; Douglas S; Harrap R; Oates A; Young I; James J; Whyte G
    Transfusion; 1992 Oct; 32(8):755-9. PubMed ID: 1412684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography.
    Burnouf T; Burnouf-Radosevich M; Huart JJ; Goudemand M
    Vox Sang; 1991; 60(1):8-15. PubMed ID: 1905084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
    Mason EC; Pepper DS; Griffin B
    Thromb Haemost; 1981 Aug; 46(2):543-6. PubMed ID: 6795742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and small-scale production of a severely heated factor VIII concentrate.
    Knevelman A; de Wit HJ; Potstra P; vd Does JA
    Vox Sang; 1994; 66(2):89-95. PubMed ID: 8184598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of large-scale fractionation methods. VI. An improved method for preparation of antihemophilic factor.
    Wickerhauser M; Mercer JE; Eckenrode JW
    Vox Sang; 1978; 35(1-2):18-31. PubMed ID: 664566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of lyophilized heat-treated cryoprecipitates from a small pool of plasma obtained by apheresis.
    Allersma DP; Roeffen E; Van der Does JA; Briët E
    Pharm Weekbl Sci; 1991 Feb; 13(1):18-23. PubMed ID: 1903526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Blood protein technological industrial developments as a mirror of fundamental studies bgy the Institute of Biochemistry of the Ukrainian National Academy of Sciences].
    Volkov GL; Andrianov SI; Horoshnykova TV; Borysevych OS; Gavryliuk OS
    Ukr Biokhim Zh (1999); 2000; 72(4-5):109-21. PubMed ID: 11200439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives.
    Schwinn H; Smith A; Wolter D
    Arzneimittelforschung; 1989 Oct; 39(10):1302-5. PubMed ID: 2514695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of wet pasteurization of a factor VIII concentrate produced by controlled-pore silica adsorption.
    Hiemstra H; Nieuweboer CE; Idoe MA; Claassen JE; Vos AH; Tersmette M; Strengers PF; Over J; Mauser-Bunschoten EP; Heijboer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):557-63. PubMed ID: 1714860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.